Oxford, UK – 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the date of its Capital Markets Day and participation at upcoming investor conferences. Capital Markets Day OXB will hold its Capital Markets Day at the London Stock Exchange Group (LSEG)… Read More
Revenues expected to increase c.30% as OXB continues to execute its strategy, FY 2025 revenues expected to be £166-169 million (£168 – 171 million CC1), at the upper end of guidance of £160-170 million (CC) (FY 2024: £128.8 million) FY 2025 Operating EBITDA2profitability expected to be mid-to-high single-digit £ million… Read More
OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmes Multi-year agreement with five-year initial term and option to extend Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has expanded its strategic… Read More
Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to… Read More
Oxford, UK – 27 October 2025:OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that members of its senior management team, including Dr. Frank Mathias, Chief Executive Officer, and Dr. Lucy Crabtree, Chief Financial Officer, will participate in the following upcoming investor… Read More
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and fill-finish to meet growing client demand Strengthens OXB’s global CDMO network and enhances service offering for existing and prospective clients… Read More
Strong H1 2025 financial results, confirming confidence in the near and medium-term outlook Total revenues in H1 2025 increased by 44% to £73.2 million (£73.4 million constant currency) (H1 2024: £50.8 million), demonstrating continued momentum £149 million contracted value of client orders1 signed during H1 2025 (+166% y-o-y, H1 2024:… Read More
Up to $125 million Oaktree loan facility to support OXB’s global CDMO operations and growth strategy $60 million upfront to repay existing $50 million loan facility and for general corporate purposes Facility provides flexibility to draw down additional funds to support future business needs, if required Oxford, UK – 1… Read More
Continued commercial, financial and operational momentum as OXB executes on its multi-vector, multi-site strategy H1 2025 revenues of £70-73 million, an increase of 38%-44% vs. £51 million at H1 2024 Commercial momentum accelerating, with £149 million new orders1 signed during H1 2025, more than double the £56 million orders signed… Read More
Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has acquired the remaining 10% stake in its US subsidiary from Q32 Bio, Inc. (Q32), bringing its ownership, as planned, to 100%. As previously disclosed in… Read More
Oxford, UK – 16 June 2025: OXB has been ranked 34th out of 300 organisations in Fortune’s list of Europe’s most innovative companies, a recognition that underscores the company’s leadership in cell and gene therapy innovation. The list, compiled based on evaluations by industry experts and employees, highlights businesses delivering… Read More
Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK The Company remains on track to deliver the outlook set out in the Preliminary Results published on 9 April 2025 Oxford, UK – 11 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell… Read More